GRCL News and Press, Gracell Biotechnologies Inc. From 11/16/23

Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA dual-targeting approach in the treatment of systemic lupus erythematosus (SLE) SAN DIEGO and S...

2023-11-13 20:50:08 ET Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Conference Call November 13, 2023, 08:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie - CFO Conference Call Participants ...

2023-11-13 10:50:32 ET More on Gracell Biotechnologies Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar Gracell draws Buy at Stifel on upcoming readout for lead asset Seeking Alpha’s Quant Rating on Gracell Biotechnologies Historical ea...

Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023 Prese...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Gracell Biotechnologies Inc. (GRCL) is expected to report $-0.26 for Q3 2023

Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is currently being evaluated in clinical studies in multiple hematological cancers as well as au...

Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous c...

Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo ...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of...